Skip to content

Precigen PGEN Common Stock, Shares, Outstanding

Common Stock, Shares, Outstanding at other companies

Gilead Sciences logo
Gilead SciencesGILD
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Roivant Sciences logo
Roivant SciencesROIV
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesOutstanding.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's common stock, shares, outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's common stock, shares, outstanding?
Precigen (PGEN) reported common stock, shares, outstanding of $355.9M in Q1 2026.
How has Precigen's common stock, shares, outstanding changed year-over-year?
Precigen's common stock, shares, outstanding increased by 20.6% year-over-year, from $295.14M to $355.9M.
What is the long-term trend for Precigen's common stock, shares, outstanding?
Over 5 years (2020 to 2025), Precigen's common stock, shares, outstanding has grown at a 13.5% compound annual growth rate (CAGR), from $187.66M to $353.91M.